Skip to main content

Table 1 Patient characteristics and SUVmax comparisons between or among groups

From: The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Characteristics No. of patients (n=134) Baseline SUVmax
Median IQR Pvalue*
Age     
 ≤ 50 63 (47.0%) 6.60 5.10–9.10 0.616
 > 50 71 (53.0%) 6.85 4.80–9.80  
Menstruation status     
 Pre-menopausal 53 (39.6%) 6.60 5.10–9.00 0.685
 Post-menopausal 81 (60.4%) 6.85 4.85–9.75  
Histology     
 IDC 124 (92.5%) 6.95 5.03–9.66 0.131
 ILC 6 (4.5%) 6.33 5.15–9.90  
 Others 4 (3.0%) 4.65 3.10–5.68  
Luminal subtype     
 Luminal A 75 (56.0%) 6.75 5.10–9.20 0.744
 Luminal B 59 (44.0%) 7.00 4.80–10.00  
Adjuvant/neoadjuvant therapy     
 Only CT (± RT) 4 (3.0%) 6.68 5.76–9.05 0.887
 Only HT (± RT) 6 (4.5%) 6.15 3.74–9.85  
 CT + HT (± RT) 101 (75.4%) 6.75 5.15–9.25  
 Therapy with TT 21 (15.7%) 7.00 4.75–10.25  
No 2 (1.5%) 5.50 4.50–6.50  
Relapse-free interval     
 ≤ 2 years 48 (35.8%) 6.25 4.81–9.20 0.592
 > 2 years 86 (64.2%) 7.00 5.18–9.59  
No. of metastatic sites     
 1 53 (39.6%) 6.10 4.60–9.08 0.002
 2 37 (27.6%) 6.25 4.70–8.15  
 ≥ 3 44 (32.8%) 8.40 6.21–10.73  
Visceral metastasis     
 Yes 64 (47.8%) 7.60 5.53–10.28 0.009
 No 70 (52.2%) 6.32 4.80–7.73  
  Only bone 20 (14.9%) 4.85 3.58–7.10 0.063
  Others     
  Only lymph node 18 (13.4%) 6.37 5.20–7.78  
  Only skin & soft tissue 5 (3.7%) 10.1 4.45–10.30  
  Mixed 27 (20.1%) 6.70 5.10–7.70  
  1. SUVmax: the maximum standardized uptake value; No.: number; IQR: interquartile range; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; CT: chemotherapy; RT: radiotherapy; HT: hormonal therapy; TT: target therapy.
  2. * Mann–Whitney U test (between 2 groups) or Kruskal-Wallis test (≥3 groups).